Intellia Therapeutics, Inc.
Nasdaq · Healthcare · In Vitro & In Vivo Diagnostic Substances · Cambridge, MA
NTLA chart
What traders are saying about $NTLA
Latest postsIntellia Therapeutics, Inc. news
- Intellia Therapeutics (NTLA) Completes Phase 3 Enrollment As Investors Ask If It Is Still A Bargain
Simply Wall St ·
- CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49
富途牛牛 ·
- Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
Yahoo Finance ·
- 3 Gene Editing Stocks Retail Investors Are Watching After BioAdvance
Yahoo Finance ·
- A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $27
Moomoo ·
- Intellia Therapeutics, Inc. (NTLA) Seasonal returns chart
Yahoo Finance UK ·
- Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress
Yahoo Finance ·
- Should Phase 3 Enrollment Completion Require Action From Intellia Therapeutics (NTLA) Investors?
Simply Wall St ·
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Three new hires got Intellia stock awards that vest over three years if they keep working there.
Stock Titan ·
- Intellia Therapeutics, Inc. (NTLA) Stock Forecasts
Yahoo Finance ·
Intellia Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M |
| Diluted EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 |
| Total assets (year end) | $842.1M | $1.19B | $1.30B | $1.52B |
| Cash and equivalents (year end) | $155.5M | $189.2M | $226.7M | $523.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Intellia Therapeutics, Inc.
- Ticker
- NTLA (Nasdaq)
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1652130
Frequently asked questions
What exchange is Intellia Therapeutics, Inc. listed on?
Intellia Therapeutics, Inc. trades on the Nasdaq under the ticker symbol NTLA.
What industry is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. is classified by the SEC under "In Vitro & In Vivo Diagnostic Substances", part of the Healthcare sector on StockTweeting.
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Intellia Therapeutics, Inc.'s fiscal year end?
Intellia Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Intellia Therapeutics, Inc. report?
Intellia Therapeutics, Inc. reported $67.7M in revenue for calendar year 2025, according to its SEC filings.